ABEONA THERAPEUTICS INC. (ABEO) Operating Margin
- Operating margin · 12 months: Value -327.64%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -327.64% | Operating income / revenue. Period ending 2026-06-30. $-83.61M ÷ $25.52M × 100 ≈ -327.64% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -83.61M USD | Operating Income (Loss) |
| Revenue | 25.52M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 8.40M USD | Cost of Goods and Services Sold |
| Research and development | 25.50M USD | Research and Development Expense |
| Selling, general and administration | 73.43M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-83.61M | $25.52M | $8.40M | $25.50M | $73.43M | -327.64% |
| 2026-03-31 | $-92.75M | $14.54M | (m) | $26.43M | $74.75M | -637.92% |
| 2025-12-31 | $-89.45M | $5.82M | $1.53M | $26.81M | $65.03M | -1536.91% |
| 2025-09-30 | $-83.21M | (m) | (m) | $29.09M | (m) | (m) |
| 2025-06-30 | $-74.54M | (m) | (m) | $33.82M | (m) | (m) |
| 2025-03-31 | $-69.61M | (m) | (m) | $37.09M | (m) | (m) |
| 2024-12-31 | $-64.21M | (m) | (m) | $34.36M | (m) | (m) |
| 2024-09-30 | $-60.75M | (m) | (m) | $32.74M | (m) | (m) |
| 2024-06-30 | $-56.74M | (m) | (m) | $30.95M | (m) | (m) |
| 2024-03-31 | $-49.43M | (m) | (m) | $30.26M | (m) | (m) |
| 2023-12-31 | $-47.13M | $3.50M | (m) | $31.09M | (m) | -1346.71% |
| 2023-09-30 | $-46.86M | $3.57M | (m) | $29.98M | (m) | -1313.40% |
| 2023-06-30 | $-44.91M | $3.57M | (m) | $28.33M | (m) | -1258.63% |
| 2023-03-31 | $-42.36M | (m) | (m) | $26.46M | (m) | (m) |
| 2022-12-31 | $-50.91M | $1.41M | (m) | $28.96M | (m) | -3600.78% |
| 2022-09-30 | $-84.63M | (m) | (m) | $31.09M | (m) | (m) |
| 2022-06-30 | $-90.12M | (m) | (m) | $34.66M | (m) | (m) |
| 2022-03-31 | $-95.83M | (m) | (m) | $36.55M | (m) | (m) |
| 2021-12-31 | $-89.84M | $3.00M | (m) | $34.33M | (m) | -2994.53% |
| 2021-09-30 | $-57.66M | (m) | (m) | $31.87M | (m) | (m) |
| 2021-06-30 | $-49.04M | (m) | (m) | $31.86M | (m) | (m) |
| 2021-03-31 | $-47.81M | (m) | (m) | $30.53M | (m) | (m) |
| 2020-12-31 | $-81.42M | $10.00M | (m) | $30.14M | (m) | -814.20% |
| 2020-09-30 | $-83.35M | (m) | (m) | $30.50M | (m) | (m) |
| 2020-06-30 | $-94.75M | (m) | (m) | $33.45M | (m) | (m) |
| 2020-03-31 | $-106.25M | (m) | (m) | $43.65M | (m) | (m) |
| 2019-12-31 | $-77.09M | (m) | (m) | $48.57M | (m) | (m) |
| 2019-09-30 | $-78.69M | (m) | (m) | $48.43M | (m) | (m) |
| 2019-06-30 | $-77.96M | $2.19M | (m) | $50.66M | (m) | -3558.01% |
| 2019-03-31 | $-66.54M | (m) | (m) | $42.27M | (m) | (m) |
| 2018-12-31 | $-58.17M | $3.00M | (m) | $38.70M | (m) | -1940.16% |
| 2018-09-30 | $-46.30M | $5.34M | (m) | $34.93M | (m) | -866.80% |
| 2018-06-30 | $-34.74M | (m) | (m) | $25.06M | (m) | (m) |
| 2018-03-31 | $-31.17M | $3.25M | (m) | $22.95M | (m) | -959.31% |
| 2017-12-31 | $-27.84M | $837.00K | (m) | $16.99M | (m) | -3325.69% |
| 2017-09-30 | $-24.92M | $878.00K | (m) | $14.32M | (m) | -2838.04% |
| 2017-06-30 | $-24.73M | $843.00K | (m) | $13.79M | (m) | -2933.57% |
| 2017-03-31 | $-23.00M | $840.00K | (m) | $11.00M | (m) | -2738.69% |
| 2016-12-31 | $-23.88M | $889.00K | (m) | $10.65M | (m) | -2686.28% |
| 2016-09-30 | $-24.30M | $848.00K | (m) | $9.69M | (m) | -2865.80% |
| 2016-06-30 | $-25.29M | $949.00K | (m) | $8.53M | (m) | -2665.12% |
| 2016-03-31 | $-22.70M | $1.02M | (m) | $6.12M | (m) | -2232.45% |
| 2015-12-31 | $-18.55M | $1.04M | (m) | $4.71M | (m) | -1783.27% |
| 2015-09-30 | $-12.76M | $1.06M | (m) | $2.68M | (m) | -1204.91% |
| 2015-06-30 | $-7.23M | $1.01M | (m) | $1.17M | (m) | -715.74% |
| 2015-03-31 | $-3.81M | $975.00K | (m) | $642.00K | (m) | -390.26% |
| 2014-12-31 | $-3.13M | $925.00K | (m) | $333.00K | $3.71M | -338.49% |
| 2014-09-30 | $-3.35M | $853.00K | (m) | $426.00K | $3.77M | -392.50% |
| 2014-06-30 | $-3.41M | $806.00K | (m) | $589.00K | $3.62M | -423.20% |
| 2014-03-31 | $-3.90M | $1.03M | (m) | $633.00K | $4.23M | -379.92% |
| 2013-12-31 | $-3.80M | $2.04M | (m) | $884.00K | $4.83M | -186.29% |
| 2013-09-30 | $-4.34M | $2.89M | (m) | $1.05M | $5.65M | -150.35% |
| 2013-06-30 | $-4.60M | $3.57M | (m) | $1.13M | $6.43M | -128.90% |
| 2013-03-31 | $-4.13M | $3.79M | (m) | $1.58M | $5.70M | -108.94% |
| 2012-12-31 | $-4.32M | $4.40M | (m) | $2.01M | $6.02M | -98.00% |
| 2012-09-30 | $-4.79M | $3.90M | (m) | $3.09M | (m) | -122.59% |
| 2012-06-30 | $-5.62M | $4.08M | (m) | $3.69M | (m) | -137.79% |
| 2012-03-31 | $-6.42M | $3.55M | (m) | $4.05M | (m) | -180.58% |
| 2011-12-31 | $-7.88M | $1.85M | (m) | $4.20M | (m) | -426.19% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-7.76M | $481.00K | (m) | $3.35M | (m) | -1612.68% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |